{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:20:20Z","timestamp":1793031620731,"version":"4.5.0"},"reference-count":63,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The hepatitis C virus (HCV), a single-stranded RNA virus belonging to the Flaviviridae family, is a major cause of hepatocellular carcinoma (HCC) worldwide. Tumors caused by HCC have an increased mortality rate globally, which is more accentuated in Western countries. The carcinogenic potential of this virus is mediated through a wide range of mechanisms, spanning from the induction of chronic inflammation to oxidative stress and deregulation of cellular pathways by viral proteins. As the number of new infections continues unabated, HCC-related mortality should be prioritized through early detection, continued prevention of HCV transmission, and treatment of HCV with safe and efficacious direct antiviral agents (DAAs). People who inject drugs (PWID) are a significant reservoir of new HCV infections globally, and in order to eliminate hepatitis C as a global health threat, as set out by the World Health Organization, an integrated approach based on the optimization of care delivery and increased access to harm reduction and treatment for PWID is needed. Thanks to the development of safe and effective antiviral agents, eradication of the infection is now possible in almost all treated patients, leading to a significant reduction but not the elimination of the risk for HCC in cured patients. This is particularly relevant among aged populations who have cofactors of morbidity known to accelerate HCC progression, such as diabetes, obesity, and excessive alcohol consumption. Given the restless accumulation of individuals with cured HCV infection, the implementation of risk-stratified surveillance programs becomes impellent from a cost-effectiveness perspective, whereas the availability of a performant biomarker to predict HCC in cured patients remains an unmet clinical need.<\/jats:p>","DOI":"10.3390\/ijms241814404","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T21:08:36Z","timestamp":1695330516000},"page":"14404","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hepatocellular Carcinoma Prevention in the Era of Hepatitis C Elimination"],"prefix":"10.3390","volume":"24","author":[{"given":"Jeffrey V.","family":"Lazarus","sequence":"first","affiliation":[{"name":"HPAM, CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY 10027, USA"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain"},{"name":"Barcelona Institute for Global Health (ISGlobal), Hospital Cl\u00ednic, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-662X","authenticated-orcid":false,"given":"Camila A.","family":"Picchio","sequence":"additional","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal), Hospital Cl\u00ednic, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"EASL International Liver Foundation, 1203 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_2","unstructured":"The Polaris Observatory HCV Collaborators (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol., 7, 396\u2013415."},{"key":"ref_3","unstructured":"WHO (2021, July 15). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.32758","article-title":"Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH","volume":"77","author":"Tan","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and prediction to 2040","volume":"6","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_6","unstructured":"WHO (2021). Global Health Sector Strategies on viral hepatitis, 2016\u20132021, World Health Organization."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/joim.12972","article-title":"We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade","volume":"286","author":"Lazarus","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_8","unstructured":"(2023, September 12). Europe\u2019s Beating Cancer Plan: A New EU Approach to Prevention, Treatment and Care. Available online: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_21_342."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancer Liver Commission: Protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"ref_10","first-page":"100578","article-title":"What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association","volume":"4","author":"Allaire","year":"2022","journal-title":"J. Hepathol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","article-title":"Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study","volume":"73","author":"Butt","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2021173","DOI":"10.1001\/jamanetworkopen.2020.21173","article-title":"Assessment of incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis c in the era of direct-acting antiviral agents","volume":"3","author":"Chen","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_15","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"ref_17","unstructured":"WHO (2022). Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022\u20132030, World Health Organization."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: An updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: Strategic and operational considertaions","volume":"38","author":"Lazarus","year":"2018","journal-title":"Sem. Liver Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.coviro.2016.09.010","article-title":"Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma","volume":"20","author":"Bandiera","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"Lau","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.4049\/jimmunol.181.9.6435","article-title":"Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire","volume":"181","author":"Rutebemberwa","year":"2008","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00535-008-2180-y","article-title":"Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies","volume":"43","author":"Li","year":"2008","journal-title":"J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., and Omata, M. (2019). Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: A review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061358"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1038\/onc.2013.225","article-title":"Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial\u2013mesenchymal transition","volume":"33","author":"Quan","year":"2013","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"984728","DOI":"10.3389\/fimmu.2022.984728","article-title":"Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-09-2123","article-title":"Hepatitis C virus proteins modulate MicroRNA expression and chemosensitivity in malignant hepatocytes","volume":"16","author":"Braconi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.25849","article-title":"Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling","volume":"56","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kouromalis, E., Tsomidis, I., and Voumvouraki, A. (2023). Pathogenesis of hepatocellular carcinoma: The interplay of apoptosis and autophagy. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041166"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s43018-021-00251-3","article-title":"Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis","volume":"2","author":"Lida","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV Eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_36","first-page":"1183","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL recommendations on treatment of hepatitis C 2018. J. Hepatol., 69, 461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"AASLD-IDSA HCV Guidance Panel (2018). Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis., 67, 1477\u20131492.","DOI":"10.1093\/cid\/ciy585"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC surveillance after SVR in patients with F3\/F4 fibrosis","volume":"74","author":"Ioannou","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2022.06.057","article-title":"Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after hepatitis c virus cure with direct acting antivirals in patients with cirrhosis or high fibrosis-4 score","volume":"163","author":"Kim","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2022.11.003","article-title":"Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis","volume":"78","author":"Nahon","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(23)00156-0","article-title":"Utility of polygenic risk scores in UK cancer screening: A modelling analysis","volume":"24","author":"Huntley","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Singal, A.G., Llovet, J.M., Yarchoan, M., Metha, N., Heimbach, J.K., Dawson, L.A., Jou, J., Kulik, L., Agopian, V., and Marrero, J.A. (2023). AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 10.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","article-title":"The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers","volume":"23","author":"Johnson","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","article-title":"Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients","volume":"14","author":"Berhane","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semi-annual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicies","volume":"54","author":"Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2022.01.027","article-title":"Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication","volume":"77","author":"Mueller","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.cgh.2021.12.014","article-title":"Multicenter randomized clinical trial of a mailed outreach strategy for hepatocellular carcinoma surveillance","volume":"20","author":"Singal","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000506834","article-title":"A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development","volume":"9","author":"Yoon","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2021.01.041","article-title":"Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis","volume":"75","author":"Gupta","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00261-017-1339-5","article-title":"Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma","volume":"43","author":"Lee","year":"2018","journal-title":"Abdom. Radiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e220917","DOI":"10.1148\/radiol.220917","article-title":"Mendiratta-lala multicenter validation of abbreviated MRI for detecting early-stage hepatocellular carcinoma","volume":"307","author":"Yokoo","year":"2023","journal-title":"Radiology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1080\/03007995.2022.2124070","article-title":"Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosis","volume":"38","author":"Nguyen","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2022.08.036","article-title":"Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?","volume":"78","author":"Parikh","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMra2302038","article-title":"Artificial intelligence and machine learning in clinical medicine, 2023","volume":"388","author":"Haug","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nahon, P., Quang, E.V., and Ganne-Carre, N. (2021). Stratification of hepatocellular carcinoma risk following HCV eradication or HBV. Control J. Clin. Med., 10.","DOI":"10.3390\/jcm10020353"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yeo, Y.H., Samaan, J.S., Ng, W.H., Ting, P.-S., Trivedi, H., Vipani, A., Ayoub, W., Yang, J.D., Liran, O., and Spiegel, B. (2023). Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma. Clin. Mol. Hepatol., ahead of print.","DOI":"10.1101\/2023.02.06.23285449"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14404\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:12Z","timestamp":1760129712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":63,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241814404"],"URL":"https:\/\/doi.org\/10.3390\/ijms241814404","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}